
Index

A

- Abstinence, 291–293
- Acetaldehyde, 42–44
 - accumulation of, 250
 - adduct formation, 250–251
 - DNA adduct formation, 252
- Acidic sphingomyelinase (ASMase), 49, 86
- Acute alcoholic hepatitis (AAH), 237–240
- Acute kidney injury (AKI), 204
- Acute-on-chronic liver failure (ACLF), 176
- Adipokines, 90
- Adiponectin, 50, 343
- Adiponutrin (PNPLA3), 197
- Adipose tissue, 45–46
- Aging, 23, 31
 - alcoholic liver disease, 169
 - in Asia, 31
 - in North America and Europe, 23
- Agouti Yellow mice, 133
- Alanine aminotransferase (ALT), 124, 198, 340
- Alcohol consumption, 174
- Alcohol dehydrogenase (ADH), 13, 42, 154, 155, 250
- Alcoholic cirrhosis, 169, 170, 172, 174
 - clinical phenotypes, 197
 - diagnosis of, 200
 - management and treatment, 203
- Alcoholic fatty liver disease (AFLD)
 - epigenetic mechanisms, 155–158
 - ethanol metabolism, 154–155
 - lipogenesis, 149
 - miRNAs, 158, 160
 - mitochondrial dysfunction, 158
 - pathogenic mechanisms, 147, 148
 - PNPLA3* gene, 149–151
 - triglycerides, abnormal deposition of, 147–149
- Alcoholic foamy degeneration, 237
- Alcoholic hepatitis (AH), 41
 - acute prognostic implication, 175
 - AST–ALT, 168
 - cirrhosis, 103
 - clinical trial design and implementation, 304–305
 - clinical trials data, 302–303
 - corticosteroids, 295
 - GI bleeding, 298
 - infection, 297–298
 - development, 175
 - diagnosis of, 201
 - histological induction, 115
 - infection, prevention and early treatment, 205
 - laboratory finding, 167
 - liver transplantation, 299
 - management and treatment
 - benzodiazepines, 204
 - corticosteroids, 204
 - improved short-term mortality, 204
 - prednisolone and pentoxifylline, 204
 - non-severe, 176
 - novel therapies, 299–304
 - alcohol on the gut, 300
 - hepatocyte cell death pathways, 304
 - inflammation and immunity, 300–304
 - modulation of steatosis, 300
 - ongoing clinical trials, 205, 206
 - physical exam, 167
 - signs and symptoms, 166
 - treatment
 - abstinence, 291–293
 - nutritional support, 293–294
 - pentoxifylline, 298–299
- Alcoholic hepatitis histological score (AHHS), 201
- Alcoholic hypoglycemia, 253
- Alcoholic liver disease (ALD), 41
 - AAH, 237–240
 - adaptive immune response, 195
 - age and gender differences, 169
 - alcoholic steatohepatitis, 2
 - alcoholic steatosis/fatty liver, 2
 - animal model (*see* Animal models of ALD)
 - BMI, 172
 - cell death
 - apoptosis, 57
 - inflammasome, 58
 - necrosis and necroptosis, 57
 - cholangiocarcinoma, 242

- Alcoholic liver disease (ALD) (*cont.*)
- clinical endpoints in patient with, 196, 205
 - alcoholic cirrhosis, 203
 - alcoholic hepatitis (*see* Alcoholic hepatitis (AH))
 - prolonged alcohol abstinence, 202–203
 - reverse fibrosis progression, 203
 - clinical history, 166
 - clinical phenotypes, 197
 - clinical spectrum of, 165
 - clinical trial design and implementation, 304–305
 - conceptual model, 2, 3
 - defined, 41
 - diagnostic approaches, 165, 205, 236
 - alcoholic cirrhosis, 200
 - early stages, 198
 - extrahepatic alcohol-induced organ damage, 201–202
 - imaging techniques, 199
 - laboratory tests, 198
 - liver biopsy, 199–200
 - physical examination, 198
 - diet/nutrition, 170–171
 - epidemiological studies, 1
 - alcohol consumption, estimation of, 4
 - mortality statistics, 3, 4
 - epigenetic changes, 172–173
 - ethanol metabolism
 - acetaldehyde oxidation, 42–43
 - alcohol oxidation pathways, 42
 - antioxidant defenses, 44–45
 - CYP2E1, 42
 - electron leakage, 43
 - oxidative stress and alcohol toxicity, 43
 - prooxidant enzymes, 44
 - prooxidant metabolites, 44
 - excess weight, 172
 - extracellular matrix (*see* Extracellular matrix (ECM))
 - fibrosis and cirrhosis, 240–241
 - genetic variations, 172–173
 - hepatocellular carcinoma, 242, 249–250
 - histological patterns of, 238
 - histological spectrum of, 235–236
 - HSCs, 42
 - imaging, 168
 - incidence, 195
 - inflammation (*see* Inflammation)
 - laboratory finding, 167–168
 - liver biopsy, 168
 - liver fat homeostasis, 45 (*see* Liver fat homeostasis)
 - liver transplantation, 299
 - macrophage activation, 41
 - management, 196
 - medications, 174
 - modifiers, 169
 - NAFLD vs., 236
 - natural history of, 174–177
 - noninvasive methods, 3
 - novel therapies, 299–304
 - alcohol on the gut, 300
 - hepatocyte cell death pathways, 304
 - inflammation and immunity, 300–304
 - modulation of steatosis, 300
 - obesity, 172
 - occupational/environmental exposure, 173–174
 - PAI-1, 58
 - panlobular fibrosis, 200
 - physical exam, 167
 - prevalence, 3
 - race/ethnicity, 170
 - risk factors (*see* Risk factors)
 - smoking, 171–172
 - spectra of, 103
 - steatosis, 236–237
 - symptoms of, 166
 - treatment, 291
 - abstinence, 291–293
 - corticosteroids (*see* Corticosteroids)
 - nutritional support, 293–295
 - pentoxifylline, 298–299
 - zinc deficiency, 170–171
- Alcoholic polyneuropathy, 202
- Alcoholic steatohepatitis (ASH)
- clinical phenotypes, 197
 - and fibrosis, noninvasive technique for, 199
- Alcoholic steatosis, 166, 175
- Alcohol metabolism
- hepatocellular carcinoma, 250
 - acetaldehyde generation/adduct formation, 250–251
 - derangement of metabolic pathways, 253–254
 - epigenetic modifications, 255–256
 - metabolic enzymes, variations in, 254–255
 - in NADH/NAD⁺ ratio, 253
 - and UADT cancer, 264
- Alcohol Use Disorder Inventory Test (AUDIT), 198
- Alcohol use disorders (AUD), 171
- Alcohol Use Disorders Identification Test (AUDIT), 166
- ALD. *See* Alcoholic liver disease (ALD)
- All-cause mortality, 216
- Alström syndrome, 133
- American lifestyle-induced obesity syndrome (ALIOS), 127
- AMP-activated protein kinase (AMPK)
- adiponectin, 50
 - definition, 49
 - PP2A and ceramide, 50
 - SIRT1, 51
- Angiotensin antagonists, 325–326
- Animal models of ALD
- conceptual requirements, 103–104
 - cyclical phenomenon, 108
 - future perspective, 116
 - historical perspective, 104, 105
 - chronic ethanol plus binge, 107–108
 - ethanol gavage for forced administration, 104
 - iG model, 106–107
 - miniature pig model, 106
 - subhuman primate models, 105–106
 - sustained BACs, 106–107

- requirements for, 104
 - rodent model (*see* Rodent alcoholic liver disease (ALD) models)
 - Anorexia, 170
 - Antifibrotic therapies, 203
 - Antinuclear antibodies (ANA), 185
 - Anxiety disorders, 212
 - Apoptosis, 57
 - AshTest, 199
 - Aspartate aminotransferase (AST), 184, 198
 - Atherogenic diet, 128
 - Autophagy, 52, 77, 85
- B**
- Ballooning hepatocellular injury, 226–228
 - Benzodiazepines, 204
 - Bile acids, 77–78
 - Binge, 111
 - chronic ethanol plus, 107–108
 - pattern, 103
 - western diet hybrid feeding model and, 114–116
 - Blood ethanol concentrations (BACs), 103
 - animal models of ALD, 106–107
 - cyclical peak, 107
 - Body mass index (BMI)
 - alcoholic liver disease, 172
 - NAFLD
 - in Asia, 29, 32
 - in North America and Europe, 24
 - Bone mineral density (BMD), 187
 - Breast cancer, 262–263
- C**
- Carbohydrate-deficient transferrin (CDT), 168
 - Carbohydrate response element-binding protein (ChREBP), 47–48, 75
 - Cardiomyopathy, 201
 - Cardiovascular disease (CVD), 313
 - in Asia, 33
 - associated with NAFLD, 186
 - in North America and Europe, 25
 - pediatric NAFLD
 - cardiac function and, 354
 - dyslipidemia, 353
 - hypertension, 353
 - left ventricular mass, 354
 - Carnitine palmitoyl transferase 1 (CPT1), 49
 - CDT. *See* Carbohydrate-deficient transferrin (CDT)
 - Cenicriviroc (CVC), 327
 - Ceramide, 49
 - Child-Pugh-Turcotte (CPT) score, 218
 - Children, NAFLD and
 - biomarkers, 348, 349
 - clinical features
 - acanthosis nigricans, 346
 - obesity, 346
 - physical examination, 347
 - diagnosis, 339–340
 - genetics, 344
 - heritability, 343
 - maternal factors and breastfeeding, 346
 - PNPLA3 (*see* Patatin-like phospholipase 3 (PNPLA3))
 - histology, 339–340
 - liver imaging, 348
 - MRI, 350
 - ultrasound, 348
 - outcomes
 - advanced fibrosis and cirrhosis, 353
 - cardiac complications (*see* Cardiovascular disease (CVD))
 - endocrine, 354–355
 - hepatocellular carcinoma, 353
 - mortality, 353
 - obstructive sleep apnea, 354
 - psychological, 355
 - pathogenesis
 - Hedgehog signaling, 341
 - inflammatory cytokines (*see* Inflammatory cytokines)
 - insulin resistance, 342
 - intestinal microbiome, 343
 - prevalence
 - age, 341
 - autopsy based study, 340
 - gender, 341
 - NASH, 341
 - race and ethnicity, 341
 - screening technique, 347–348
 - treatment, 351
 - bariatric surgery, 352
 - dietary supplements, 352
 - lifestyle interventions, 350
 - pharmacologic therapy (*see* Pharmacologic therapy)
 - Child–Turcotte–Pugh (CTP), 175, 176
 - Cholangiocarcinoma, 242, 284
 - Cholecystokinin 1 (CCK-1) gene, 134
 - Choline-deficient L-amino aciddefined (CDAA) diet, 129
 - Chronic alcoholic myopathy, 201
 - Chronic ethanol plus binge, 107–108
 - Chronic hepatitis C, 232
 - Chronic kidney disease (CKD), 186–187
 - Cigarette smoking, 171–172
 - Circadian rhythm, 259–260
 - Cirrhosis, 218
 - ALD, 240–241
 - laboratory finding, 167
 - physical exam, 167
 - signs, 166
 - symptoms, 166, 167
 - VA Cooperative Study with, 177
 - Colon cancer, 263
 - Colorectal cancer (CRC), 263
 - Computed tomography (CT)
 - alcoholic liver disease, 168
 - of liver, 213
 - Conjugated linoleic acid (CLA), 128

Controlled attenuation parameter (CAP), 199, 214

Corticosteroids

in AH patients, 295

with GI bleeding, 298

with infection, 297–298

non-responders to, 296–297

steroid controversy, 295–296

Cryptogenic cirrhosis

case reports and case series, 277

longitudinal studies, 274–277

transversal studies, 277

Cysteamine, 351

Cysteamine bitartrate, 327

Cytochrome P450, family 2, subfamily E, polypeptide 1 (CYP2E1), 42, 155, 250

Cytochrome P450 isozymes, 250

Cytosine (C) methylation, 155

D

Damage-associated molecular patterns (DAMPs), 58

Death certificate, 4

Death receptor

apoptosis

ER stress, 83–85

intrinsic, 83

induction and activation

Fas receptor, 81

TNF, role of, 82–83

TRAIL receptor, 81

necroptosis, 83

Depression, 212

Diabetes mellitus (DM)

associated with NAFLD, 185

HCC, 273–274

NAFLD

in Asia, 33

in North America and Europe, 25

Diet and physical activity

alcoholic liver disease, 170–171

NAFLD

in Asia, 33

in North America and Europe, 26

Dietary animal model

atherogenic diet, 128

choline-deficient L-amino aciddefined diet, 129

conjugated linoleic acid, 128

high-fat diet model

combined methionine-choline-deficient and

high-fat diet, 128

regular high-fat diet, 125–127

Western/fast-food diet, 127–128

intake, 45

methionine-choline-deficient diet model, 122–125

DNA methylation, 172, 173, 256

DNA methyltransferases (DNMT), 257

Drug abuse, alcoholic liver disease, 174

Dysbiosis, 55

Dyslipidemia, 353

E

Electron transport chain (ETC), 251, 252

Endocannabinoid system, 49

Endoplasmic reticulum (ER), 46, 47

Endotoxin, 79

Enhanced liver fibrosis test, 321

Environmental exposure, 173–174

Epigenetic changes, alcoholic liver disease, 172–173

Epigenetic effects, 257–259

Epigenetic mechanisms, 155–158

Epigenetic modifications, alcohol metabolism, 255–256

Ethanol

animal models of ALD, 104

in drinking water model, 104, 111

metabolism, 154–155, 251

Ethnicity

alcoholic liver disease, 170

NAFLD

in Asia, 27

in North America and Europe, 23

Exenatide, 326–327

Extracellular matrix (ECM)

complement cascade, 59–60

fibrin metabolism, 60–61

inflammatory liver damage, 59, 60

osteopontin, 61

PAI-1 and hepatic fibrosis, 59

role of, 59

Extrahepatic malignancy, and end-stage liver disease (ESLD), 313

F

Farnesoid X receptor (FXR), 48, 321

Fat aussie (Alms1 foz/foz) mice, 133

Fatigue, 212

Fatty acid transporters, 46

Fatty liver inhibition of progression (FLIP), 235

FIB4, 213

Fibrates, 324

Fibrinolysis, 60

Fibroblast growth factor 21 (FGF21), 327

Fibroscan[®], 199, 214

Fibrosis, 218, 228, 240–241

FibroTest[®], 199

Forkhead box O1 (FOXO1), 74

Fructose, 315

G

Gastric alcohol dehydrogenase (ADH) activity, 169

Gender

alcoholic liver disease, 169

NAFLD

in Asia, 32

in North America and Europe, 23, 24

Genetic factors, 12

alcohol metabolizing enzymes

ADH, 13

- ALDH, 13
 - cytochrome p450E1, 13
 - innate immune system, 14
 - lipid metabolism, PNPLA3, 14–15
 - oxidative stress, 14
 - Genetic models
 - cystathionine β -synthase (CBS) deficient mice, 136
 - disadvantage, 137
 - interleukin-6 deficient mice, 136
 - with lipodystrophy-like phenotype, NAFLD
 - aP2-diphtheria toxin mice, 134
 - A-ZIP/F1 mice, 134
 - CD36-deficient mice, 134
 - SREBP-1c transgenic mice, 134
 - methionine adenosyltransferase 1A deficient mice, 135
 - NEMO deficient mice, 136
 - with primary altered lipid metabolism
 - acyl-coenzyme A oxidase-deficient mice, 135
 - microsomal trifunctional protein-deficient mice, 135
 - PPAR- α -deficient mice, 135
 - PTEN null mice, 135
 - Genetic polymorphisms, in ADH and ALDH family, 155
 - Genetic variations, alcoholic liver disease, 172–173
 - Genome-wide association study (GWAS), 14, 152–154, 172, 261
 - GFT505, 327
 - Glasgow alcoholic hepatitis score (GAHS), 176
 - Global burden of disease study, 3
 - Glutathione (GSH), 252, 327
 - Glutathione-S-transferase (GST), 257
 - GR-MD-02, 326
- ## H
- Heavy drinking, 249
 - Hedgehog signaling, 341
 - Hepatic lipid synthesis
 - ASMase, 49
 - ChREBP, 47–48
 - de novo lipid synthesis, 46
 - endogenous cannabinoids, 49
 - FXR, 48
 - LXR, 48
 - SREBP-1c, 46–48
 - Hepatic lipid uptake
 - adipose tissue, 45–46
 - dietary intake, 45
 - fatty acid transporters, 46
 - Hepatic steatosis
 - adipocyte dysfunction in obesity, 72
 - lipodystrophy, 73
 - TNF insulin signaling, 73
 - visceral fat and visceral obesity, 73
 - adipose tissue insulin resistance, 74
 - de novo lipogenesis, 74
 - gluconeogenesis, 73
 - hyperinsulinemia, 73
 - lipid synthesis, 73, 74
 - and autophagy, 77
 - behavioral factors affecting
 - dietary nutrients, intake of, 79–80
 - diurnal clock and timing of food intake, 80–81
 - endoplasmic reticulum stress, 75
 - adaptive responses, 75
 - lipid synthesis, 76
 - regulations, 76
 - signaling, 77
 - and SREBP1 activation, 76
 - factors, 76
 - genetics, 78–79
 - gut microbiome, 79
 - regulation of lipid metabolism by bile acids, 77–78
 - Hepatic stellate cells (HSCs), 42
 - Hepatic venous pressure gradient (HVPG), 218, 219
 - Hepatitis B, 12
 - Hepatitis C, 11–12, 174
 - Hepatocarcinogenesis, 90
 - Hepatocellular adenomas (HCAs), 281–283
 - Hepatocellular carcinoma (HCC)
 - alcohol consumption, 249–250
 - alcohol metabolism, 250
 - acetaldehyde generation/adduct formation, 250–251
 - derangement of metabolic pathways, 253–254
 - epigenetic modifications, 255–256
 - metabolic enzymes, variations in, 254–255
 - in NADH/NAD⁺ ratio, 253
 - oxidative stress, 251–253
 - RNS formation, 251–253
 - ROS formation, 251–253
 - circadian rhythm perturbation, 259–260
 - epigenetic effects, 256
 - DNA methylation, 256–257
 - histone modification, 257–259
 - miRNAs, 259
 - immune modification, 260–261
 - incidence, 273
 - NAFLD and children, 353
 - NASH-cirrhosis and cryptogenic cirrhosis, 274
 - case reports and case series, 277
 - longitudinal studies, 274–279
 - non-cirrhotic NASH, 277–281
 - transversal studies, 277
 - neovascularization, 261–262
 - obesity and diabetes, 273–274
 - risk factor, 273
 - surveillance for, 168
- Hepatocyte growth factor (HGF), 53
- Hepatocytes, 56
- Hereditary hemochromatosis, 174
- High-fat diet model
 - advantage, 129
 - combined methionine-choline-deficient and high-fat diet, 128
 - regular high-fat diet, 125–127
 - Western/fast-food diet, 127–128
- Histone acetyltransferases (HATs), 258
- Histone modification, alcohol metabolism, 257–259
- Homocysteine, 47
- Hypertension, 353

I

- IkB kinase (IKK), 136
- Immune system, in HCC, 260–261
- Inflammasome, 58
- Inflammation
 - alcohol-induced endotoxemia, 54
 - barrier function, 56
 - dysbiosis, 55
 - microRNA, 57
 - priming and sensitization, 56–57
- Inflammatory cytokines
 - leptin and adiponectin, 343
 - PPAR- γ , 343
 - resistin, 342
- Insulin resistance, 24, 33
- Intragastric (iG) feeding models
 - ALD, 106–107
 - obesity, 114
 - standard iG, 113–114
 - Western diet hybrid feeding model and, 114
- Intra-hepatic cholangiocarcinoma (IH-CCA), 284

K

- Ketoacidosis, 253
- Kupffer cells, 54

L

- Leptin, 90, 343
- Lieber-DeCarli (L/D) liquid diet model, 105, 106, 111–112
- Lille score, 176
- Linoleic acid (LA), 170
- Lipodystrophy, 231
- Lipopolysaccharide (LPS), 53, 260
- Liver-associated enzymes (LAEs), 183
- Liver biopsy, 168, 212
- Liver fat homeostasis
 - autophagy, 52
 - hepatic fatty acid oxidation, 49
 - AMPK (*see* AMP-activated protein kinase (AMPK))
 - PPARs, 51–52
 - hepatic lipid synthesis
 - ASMase, 49
 - ChREBP, 47–48
 - de novo lipid synthesis, 46
 - endogenous cannabinoids, 49
 - FXR, 48
 - LXR, 48
 - SREBP-1c, 46–48
 - hepatic lipid uptake
 - adipose tissue, 45–46
 - dietary intake, 45
 - fatty acid transporters, 46
 - triglycerides, 52–53
- Liver function tests, 219
- Liver metabolism, 260
- Liver-related mortality, 213, 218

- Liver-related outcome endpoint, 218
- Liver transplantation, 299, 322–323
- Liver X receptor (LXR), 48
- Long-chain polyunsaturated fatty acids (LC-PUFA), 325
- LPS. *See* Lipopolysaccharide (LPS)
- Lysophosphatidic acid acyltransferase (LPAAT), 78
- Lysyl oxidases (LOX), 326

M

- Macrocytosis, 167
 - Maddrey's discriminant function (DF), 168, 176, 204
 - Magnetic resonance imaging (MRI), 168, 213
 - Mallory–Denk bodies, 226
 - Malnutrition, in ALD, 170–171
 - Malondialdehyde–acetaldehyde (MAA), 44, 250, 251
 - MC4-R KO mice, 133
 - Medications, alcoholic liver disease, 174
 - Metabolically obese normal weight (MONW), 29, 31
 - Metabolic enzymes, variations in, 254–255
 - Metabolic pathways, derangement of, 253–254
 - Metabolic syndrome, 25, 33
 - Metformin, 323
 - Methionine-choline-deficient (MCD) diet model, 105
 - adipokine profile, 125
 - alanine aminotransferase, 124
 - aminotransferase elevation, 124
 - cholesterol content, 124
 - choline deficiency, 124
 - gender differences, 123
 - hepatic lipid profile, 123
 - high-sucrose content, 123
 - hypermetabolism, 124
 - hypertension, 124
 - leptin activity, 125
 - lipid profile, 125
 - liver fibrosis, 123
 - low doses of lipopolysaccharide, 125
 - phosphatidylcholine, 123
 - steatosis, 123
 - Mice fed homocysteine, 47
 - Microbiome, 55
 - Microgranulomas, 224
 - MicroRNA, 57, 158, 259
 - Microsomal ethanol oxidizing system (MEOS), 42
 - Miniature pig model, 106
 - Mitochondrial DNA (mtDNA), 111
 - Mitochondrial manganese superoxide dismutase (MnSOD), 252
 - Mitochondrial NADH, 250
 - Model for end stage liver disease (MELD) score, 176, 218–219
 - MS-linked non-communicable diseases, 27
- N**
- NAD(P)H oxidase (NOX2), 44
 - NAFLD activity score (NAS), 185, 217, 340
 - NASH Clinical Research Network (NASH CRN), 340, 341

- National Health and Nutrition Examination Survey (NHANES), 340
- National Institute on Alcohol Abuse and Alcoholism, 166
- Necroinflammatory process, 175
- Necroptosis, 57
- Necrosis, 57
- Neoangiogenesis, 261–262
- Nitric oxide (NO), 252
- Nitric oxide synthase (NOS2), 44
- Non-alcoholic fatty liver disease (NAFLD)
- in adults
 - ballooning hepatocellular injury, 226–228
 - fibrosis, 228
 - histopathological features of, 223
 - inflammation, 224–226
 - steatosis, 224
 - age
 - in Asia, 31
 - in North America and Europe, 23
 - vs. ALD, 236
 - angiotensin antagonists, 325–326
 - anthropometric parameters, 27
 - associated clinical conditions
 - bone mineral density, 187
 - CKD, 186–187
 - colonic adenomas, 187
 - CVD, 186
 - diabetes mellitus, 185
 - elevated uric acid levels, 188
 - endocrine -related disorders, 188
 - myriad of extra-hepatic conditions, 188
 - obstructive sleep apnea, 186
 - polycystic ovarian syndrome, 187, 188
 - vitamin D deficiency, 187
 - bariatric surgery, 318
 - in biopsy studies, 232–234
 - BMI
 - in Asia, 29, 32
 - in North America and Europe, 24
 - cardiovascular disease
 - in Asia, 33
 - in North America and Europe, 25
 - centriciviroc, 327
 - changes in lifestyle, 27
 - characterization, 122
 - Child-Pugh-Turcotte score, 218
 - in children, 229–231
 - cirrhosis, 122, 184
 - clinical presentation
 - diagnosis, 184
 - medication, 184
 - non-invasive tests, 185
 - prevalence, 183
 - symptoms, 184
 - cysteamine bitartrate, 327
 - depression and anxiety disorders, 212
 - diabetes
 - in Asia, 33
 - in North America and Europe, 25
 - diet and physical activity, 130
 - in Asia, 33
 - in North America and Europe, 26
 - dietary animal model (*see* Dietary animal model)
 - drug specific assessment of response, 219
 - epidemiologic studies, 122
 - epigenetic mechanisms, 155–158
 - ethnicity
 - in Asia, 27
 - in North America and Europe, 23
 - exenatide, 326–327
 - extrahepatic malignancies, 285
 - fatigue, 212
 - features of, 225
 - fibrates, 324
 - fibroblast growth factor 21, 327
 - gender
 - in Asia, 32
 - in North America and Europe, 23, 24
 - genetic models
 - Agouti Yellow mice, 133
 - db/db mice, 132
 - fa/fa Zucker rats, 132
 - Fat aussie (Alms1 foz/foz) mice, 133
 - with lipodystrophy-like phenotype, 134
 - MC4-R KO mice, 133
 - ob/ob mice, 129–132
 - OLETF rats, 134
 - primary altered lipid metabolism, 135
 - GFT505, 327
 - global methylation profiling, 157
 - glycogenesis of, 229
 - goals of treatment, 313
 - grading and staging systems for, 234
 - GR-MD-02, 326
 - GWAS, 152–154
 - heritability, 154
 - HVPG measures, 219
 - incidence
 - in Asia, 29–31
 - in North America and Europe, 21–23
 - insulin resistance
 - in Asia, 32
 - in North America and Europe, 24
 - intervention, 213–214
 - lipogenesis, 149
 - liver directed therapies
 - obeticholic acid, 321–322
 - thiazolidinediones, 319–321
 - vitamin E, 319
 - weight loss, 314–319
 - liver related response, 215
 - liver transplantation, 322–323
 - long-chain polyunsaturated fatty acids, 325
 - malignancy-related morbidity and mortality, 271
 - MELD score, 218–219

Non-alcoholic fatty liver disease (NAFLD) (*cont.*)
 metabolic comorbidities and environmental risks, 327–328
 metabolic syndrome
 in Asia, 32, 33
 in North America and Europe, 25
 metformin, 323
 miRNAs, 158, 160
 mitochondrial dysfunction, 158
 MS-linked non-communicable diseases, 27
 natural history, 188–190
 non-rodent models, 137–138
 obesity, 212
 in Asia, 32
 in North America and Europe, 24
 outcomes and endpoints
 assessment of, 214–217
 early phase (1-2a) trials, 217
 for early stage, 217
 fibrosis/cirrhosis as intermediate-term endpoint, 218
 histology-based endpoints, 217–218
 liver-related outcome endpoint, 218
 patient functions, 215–216
 patient survives, 216
 patient with NASH feels, 215
 pathogenic mechanisms, 147, 148
 in patients with lipodystrophy, 231
 pentoxifylline, 326
 physical examination, 212
PNPLA3 gene, 149–151
 presence of, 212–213
 prevalence
 in Asia, 27–29
 in North America and Europe, 21, 22
 quantitative liver function tests, 219
 rs738409 variant, 150
 SAF diagnostic algorithm for, 235
 simtuzumab, 326
 socioeconomic affluence, 27
 sonographic features, 213
 staging and grading in, 234–235
 statins, 324
 suspecting, 212
 symptoms, 212
 synergism in liver disease progression, 27
 triglycerides, abnormal deposition of, 147–149
 ursodeoxycholic acid, 323–324
 zone 1 pattern of injury, 230

Non-alcoholic steatohepatitis (NASH)
 cell death mechanism, 81
 acidic sphingomyelinase, 86
 autophagy, 85
 death receptor (*see* Death receptor)
 mitochondrial dysfunction and necrosis, 85
 pyroptosis, 85
 cirrhosis, 274–277
 early phase (1-2a) trials, 217
 early stage, 217

grading and staging systems for, 234
 hepatic fibrosis, 89
 adipokines, 90
 hepatocyte death, 84, 89
 hepatic inflammation
 innate immune system, 86
 Kupffer cells, 88–89
 role in steatohepatitis, 87–88
 toll-like receptor, 86–87
 hepatocarcinogenesis, 90
 obeticholic acid for, 214
 outcomes and endpoints, 215
 SAF diagnostic algorithm for, 235

Non-rodent models
 fish models, 137, 138
 opossum model, 137
 ossabaw pigs, 137

Nutrition, 170–171

O

Obesity
 alcoholic liver disease, 172
 HCC, 273–274
 NAFLD
 in Asia, 32
 in North America and Europe, 24
 pediatric, 346, 350
 Obeticholic acid (OCA), 214, 321–322
 Obstructive sleep apnea (OSA)
 associated with NAFLD, 186
 in children, 354
 Occupational exposure, 173–174
 Osteopontin, 61
 Otsuka Long-Evans Tokushima fatty (OLETF) rats, 134
 Overweight, 172
 Oxidative pathways, of ethanol metabolism, 251
 Oxidative stress
 ethanol metabolism
 acetaldehyde oxidation, 42–43
 alcohol oxidation pathways, 42
 alcohol toxicity, 43
 antioxidant defenses, 44–45
 enzyme-catalyzed transfer, 43
 molecular oxygen, 43
 prooxidant enzymes, 44
 prooxidant metabolites, 44
 formation, 251–253

P

Paigen diet. *See* Atherogenic diet
 Patatin-like phospholipase 3 (*PNPLA3*)
 adiponutrin, 14–15
 cellular lipid synthesis, 150
 function of, 150
 Met148 variant, 151
 patatin-like phospholipase domain-containing 3, 78
 pediatric NAFLD, 345

ALT and, 344
 diet, 345
 imaging and histology, 344–345
 silencing of, 151

Pathogenesis
 hepatic steatosis, 72
 adipose tissue dysfunction, 72–73
 adipose tissue insulin resistance, 73–75
 autophagy and, 77
 behavioral factors, 79–81
 endoplasmic reticulum stress, 75
 ER stress, 75–77
 genetics, 78–79
 gut microbiome, 79
 regulation of lipid metabolism by bile acids,
 77–78

NASH, liver injury in, 81
 cell death, mechanism of, 81–86
 hepatic fibrosis, 89
 hepatic inflammation, 86–89
 hepatocarcinogenesis, 90

Pentoxifylline, 298–299, 326

Peroxisome proliferative activated receptor gamma
 coactivator 1 alpha (*PPARGC1A*), 156, 157

Peroxisome proliferator-activated receptor-gamma
 (*PPAR-γ*) agonists, 319, 343

Peroxisome proliferator-activated receptors (*PPARs*), 51

Pharmacologic therapy, 351–352

Phosphatidylcholine (PC), 52, 123

Phosphatidylethanolamine methyltransferase (*PEMT*),
 52

Pioglitazone, 52, 319, 320

Plasminogen activator inhibitor-1 (*PAI-1*), 58, 60

Plasminogen activators, 58

Polycystic ovarian syndrome (*PCOS*), 187

Polyunsaturated fatty acids (*PUFA*), 45

Protein phosphatase 2A (*PP2A*), 47, 50

Pruritus, 322

Pyroptosis, 85

R

Reactive nitrogen species
 chemical equations relevant to, 252
 formation, 251–253

Reactive oxygen species (*ROS*), 250
 chemical equations relevant to, 252
 formation, 251–253

Regular high-fat diet, 125–127

Retinoic acid (*RA*), 254, 260

Rigorous cohort studies, 1

Risk factors
 alcoholic hepatitis and cirrhosis, 12
 alcohol consumption, 7–8
 beverage type, 9
 chronic hepatitis C, 11–12
 consumption pattern, 9
 duration of heavy drinking, 8
 genetic factors (*see* Genetic factors)

hepatic iron overload, 11
 hepatitis B infection, 12
 nutritional factors, 10
 obesity, 10–11
 in women, 9
 estimation of, 2

Rodent alcoholic liver disease (*ALD*) models, 108
 acute and subacute, 108–111
 chronic binge models, 111
 chronic Lieber-DeCarli liquid diet model, 111–112
 ethanol in drinking water model, 111
 historical perspective, 104–105
 hybrid feeding models, 115
 iG catheter, 107, 114
 obesity iG, 114
 research, 109–110
 standard iG, 113–114
 Western Diet and iG hybrid feeding model, 112, 114

Rodents with disturbed appetite regulation
 Agouti Yellow mice, 133
 db/db mice, 132
 fa/fa Zucker rats, 132
 Fat aussie (*Alms1 foz/foz*) mice, 133
 MC4-R KO mice, 133
 ob/ob, 129–132
 OLETF rats, 134

Rosiglitazone, 319

S

S-adenosyl methionine (*SAMe*), 123, 124

Screening ALT for Elevation in Today's Youth
 (*SAFETY*) study, 340

Secreted phosphoprotein-1 (*SPP-1*), 61

Selective insulin resistance, 73–74

Serum CK18, 217

Severe alcohol withdrawal syndrome (*SAWS*), 9

Siderosis, 242

Simtuzumab, 326

Single nucleotide polymorphisms (*SNPs*), 14, 172

Sirtuin 1 (*SIRT1*), 51

Small intestinal bacterial overgrowth (*SIBO*), 79

Statins, 324

Steatohepatitis, 217, 223, 317

Steatosis, 53, 54, 123, 224, 231, 236–237

Steroid response element binding protein (*SREBP-1c*),
 46–48

Study of Child and Adolescent Liver Epidemiology
 (*SCALE*), 340

Subhuman primate models, 105–106

Swift increase in ethanol metabolism (*SIAM*), 111

T

Thiazolidinediones (*TZDs*), 319–321

TONIC clinical trial, 323

Toxicant-associated steatohepatitis (*TASH*), 173

Transient elastography, 214

Transitional extracellular matrix, 59

Transjugular intrahepatic portosystemic shunt (TIPS) procedures, 176

Transmembrane 6 superfamily member 2 (TM6SF2), 78

Tricarboxylic acid (TCA), 250, 253

Triglycerides (TGs), 52–53, 147–149

Type 2 diabetes, 212, 214

Type 2 steatohepatitis, 229

U

Ultrasound, 168, 285

United Network for Organ Sharing (UNOS), 176

Upper aerodigestive tract (UADT) cancer, 251, 264

Ursodeoxycholic acid (UDCA), 323–324, 351

V

Vascular endothelial growth factor (VEGF), 262

Very low density lipoprotein (VLDL), 52–53

Vinyl chloride (VC), 173

Visceral adipose tissue (VAT), 24

Vitamin A deficiency, 10

Vitamin C, 351

Vitamin D deficiency (VDD), 187

Vitamin E, 319, 351

W

Weight loss, 314–319

Wernicke's encephalopathy, 202, 204

Western diet, 113

fast-food diet, 127–128

hybrid feeding model, 114–116

rodent ALD models, 112

World Health Organization (WHO), 1

X

Xylulose-5-phosphate (Xu-5-P), 47

Z

Zinc deficiency, 10, 170–171